Corporate | 12 February 2016 07:00
Carl Zeiss Meditec AG grows, boosted by currency tailwinds / Strongest growth once again in Surgical Ophthalmology
|
DGAP-News: Carl Zeiss Meditec AG / Key word(s): Quarterly / Interim Statement/Quarter Results
Carl Zeiss Meditec AG grows, boosted by currency tailwinds / Strongest growth once again in Surgical Ophthalmology
Revenue increases by 8.9 percent (adjusted for currency effects: 3.8 percent) to EUR 262.6 million in the first quarter of the fiscal year / EBIT margin reaches 12.3 percent
Currency effects also affected earnings per share at the beginning of the year: due primarily to the negative results from currency hedges, which are offset by positive effects in the operating result, consolidated profit after non-controlling interests amounted to around EUR 16.7 million, corresponding to a decline of 8.8 percent compared with the year-ago figure.
Key figures by business segment at a glance Once again, the Surgical Ophthalmology strategic business unit (SBU) achieved the highest growth rates. Revenue climbed by 13.6 percent in the reporting period, compared with the year-ago quarter, to EUR 92.6 million (prior year: EUR 81.6 million). Even after adjustment for currency effects, this growth was still in the double digits, at 10.7 percent. Surgical workstations for optimized workflow in ophthalmology, and intraocular lenses, were once again in high demand, as were systems for optical biometry. The Ophthalmic Systems SBU increased its revenue by 7.5 percent in the reporting period, to EUR 98.6 million (prior year: EUR 91.7 million). After adjustment for currency effects, however, this growth would only have amounted to 0.7 percent. The Microsurgery SBU generated revenue of EUR 71.3 million, which corresponds to an increase of 5.2 percent compared with the year-ago figure of EUR 67.8 million; adjusted for currency effects, revenue is on a par with the prior year. Revenue by region The three global regions made varying contributions to the Company’s revenue; once again, the greatest growth came from the Asia/Pacific (APAC) region, even after adjusting for currency effects. In the EMEA region (Europe, Middle East and Africa), significant contributions to growth came in particular from Germany and the United Kingdom; development in Southern Europe was mixed. On balance, revenue in the EMEA region increased by 4.2 percent, to EUR 90.2 million (prior year: EUR 86.5 million). Revenue in the Americas region benefited from the strong U.S. dollar and – even on a currency-adjusted basis – from a positive trend in Latin America. Overall, revenue growth of 10.1 percent to EUR 88.8 million was achieved (prior year: EUR 80.6 million). Adjusted for currency effects, the region would have recorded a slight decline of 1.4 percent, because the development of the U.S. business remained subdued. The APAC region once again recorded the highest growth, increasing its revenue by 13.1 percent, to EUR 83.6 million (prior year: EUR 73.9 million). After adjustment for currency effects, this corresponds to growth of 9.1%. According to President and CEO, Dr. Ludwin Monz, the first quarter has not changed expectations for the fiscal year: “We shall continue to strive for growth that is at least on a par with market growth, and for an EBIT margin in the range of 13 to 15 percent.”
Revenue by strategic business unit
Revenue by region
Contact for investors
2016-02-12 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
|
| Language: | English | |
| Company: | Carl Zeiss Meditec AG | |
| Göschwitzer Str. 51-52 | ||
| 07745 Jena | ||
| Germany | ||
| Phone: | +49 (0)3641 220-0 | |
| Fax: | +49 (0)3641 220-112 | |
| E-mail: | investors.meditec@zeiss.com,info.meditec@zeiss.com | |
| Internet: | www.meditec.zeiss.de | |
| ISIN: | DE0005313704 | |
| WKN: | 531370 | |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart | |
| End of News | DGAP News Service |